Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) on behalf of Anavex stockholders. Our investigation concerns whether Anavex has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On February 1, 2022, before the market opened, Anavex announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints. Following the announcement, several people on social media indicated that the primary and secondary endpoints were recently changed. STAT News writer, Adam Feuerstein, tweeted, “Anavex changed the primary and secondary endpoints of this Rett study on Jan. 18, allowing it to claim success when the drug most likely failed.”
On this news, Anavex’s stock fell $2.04, or 15.6%, to close at $11.04 per share on February 1, 2022, thereby injuring investors.
If you purchased or otherwise acquired Anavex shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220202006016/en/
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
